PREVEST.BO · BSE

Prevest Denpro Limited

₹377.2

-0.47% (-₹1.8)

Prev. close

₹379

Volume

7,000

As of

BSE · may be slightly delayed · 16:00 IST

Price history

₹379-₹12 (-3.07%) · 3M
18 Jun 202621 Sept 2026
₹407₹372.918 Jun13 Jul05 Aug27 Aug21 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Prevest Denpro Limited in the last 90 days.

Fundamentals

About Prevest Denpro Limited

Prevest Denpro Limited, together with its subsidiaries, engages in the manufacturing and marketing of dental materials and allied products. The company offers clinical products, including adhesives, bonding agents, and etchants; auxiliaries; cement and liners; composites; endodontics; finishing and polishing; impression; orthodontics; retraction materials; temporaries; and tooth whitening products. It also provides laboratory products, such as acrylics, auxiliaries, base plates and waxes, and gypsum products; 3D resins; oral care; and hygiene and disinfection products. The company's products are used in endodontics, prosthodontics, periodontics, orthodontics, restorative dentistry, and aesthetic dentistry applications, as well as for fabrication of prosthesis in dental laboratories. Prevest Denpro Limited was incorporated in 1999 and is based in Jammu, India.

Details

Sector

Healthcare

Industry

Medical Instruments & Supplies

CEO

Mr. Atul Modi

Headquarters

Jammu

Employees

139

Key stats

Market cap

₹454.91 Cr

P/E ratio (TTM)

21.0

Dividend yield

0.26%

EPS (TTM)

₹18.08

Beta (1Y · daily vs NIFTY 50)

0.76

Beta (5Y · monthly vs NIFTY 50)

2.06

Shares float

21.71 L

EPS · quarter ended Jun 2026

₹4.70

Financial Performance

01 · Financials

0 Cr25 Cr50 Cr75 Cr0%10%20%30%40%FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

The first plotted growth figure is computed against Mar 2022 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY23 growth needs FY22 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

05101520FY22FY23FY24FY25FY26

03 · Dividend Profile

001110%0.1%0.2%0.3%23 Aug 2330 Aug 2403 Sept 2504 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-200%0%200%400%FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr50 Cr100 Cr150 Cr0.5×1.5×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr50 Cr100 Cr150 CrFY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

Other assets floored at zero for years where fixed and current assets exceeded reported total assets.

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-50 Cr0 Cr50 Cr100 CrFY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY22FY23FY24FY25FY26
₹37.62 Cr₹49.85 Cr₹55.91 Cr₹62.08 Cr₹70.89 Cr
EBITDA₹21.63 Cr₹22.71 Cr₹26.15 Cr₹29.62 Cr
₹11.57 Cr₹15.71 Cr₹16.14 Cr₹18.16 Cr₹20.49 Cr
Diluted EPS₹9.64₹13.09₹13.45₹15.13₹17.07

Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY22FY23FY24FY25FY26
₹7.41 Cr₹94.82 Cr₹112.53 Cr₹133.19 Cr
₹0₹0₹0₹0
Stockholders' equity₹72.80 Cr₹88.62 Cr₹105.57 Cr₹124.80 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY22FY23FY24FY25FY26
₹10.67 Cr₹11.62 Cr₹14.82 Cr₹14.81 Cr
Investing cash flow₹-12.38 Cr₹-1.70 Cr₹-1.33 Cr₹-1.59 Cr
₹-1.37 Cr₹-31.68 L₹-1.20 Cr₹-1.20 Cr
Capital expenditure₹-13.53 Cr₹-3.73 Cr₹-1.97 Cr₹-1.89 Cr
End cash position₹39.00 Cr₹48.61 Cr₹60.90 Cr₹72.85 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,846.437.15.3713.7%0.06+11.9%+12.3%
Divi's Laboratories Limited₹2.49 L Cr₹9,410.584.714.8515.3%0.00+12.3%+51.8%
Torrent Pharmaceuticals Limited₹1.84 L Cr₹4,97077.521.9525.8%1.79+21.5%+36.9%
Apollo Hospitals Enterprise Limited₹1.28 L Cr₹8,835.561.513.5220.5%0.90+15.7%+14.2%
Lenskart Solutions Limited₹1.18 L Cr₹691.45179.013.555.6%0.35+35.4%
Zydus Lifesciences Limited₹1.16 L Cr₹1,16125.84.2718.6%0.46+18.4%+11.9%
Cipla Limited₹1.12 L Cr₹1,384.133.23.2511.3%0.02+2.1%-10.3%
Laurus Labs Limited₹1.09 L Cr₹2,006.599.320.5716.8%0.48+22.0%+122.0%
Max Healthcare Institute Limited₹1.02 L Cr₹1,066.670.49.5013.4%0.32+19.0%-8.0%
Manipal Health Enterprises Limited₹99,047.90 Cr₹746.1152.111.757.8%1.53+18.0%
Dr. Reddy's Laboratories Limited₹98,709.15 Cr₹1,198.329.82.6211.4%0.21+3.2%-9.3%
Prevest Denpro Limited₹459.71 Cr₹382.321.23.6816.4%0.00+14.2%-32.2%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

No stock news captured yet.